Mendus announces positive survival data from Phase 2 ADVANCE II trial evaluating vididencel as maintenance therapy for AML at ASH 2023

Press Release Stockholm, Sweden, December 11, 2023 As of November 24, 2023, median relapse-free survival stood at 30.4 months Median overall survival was not reached, with the majority of...

Related Keywords

Netherlands ,Stockholm ,Sweden ,Amsterdam ,Noord Holland ,San Diego ,California ,United States ,Australia ,Australian ,American ,Erik Manting ,American Society Of Hematology ,Lymphoma Group ,Press Release ,American Society ,Annual Meeting ,Principal Investigator ,California December ,Jeroen Rovers ,Australian Leukaemia ,Nasdaq Stockholm ,Orphan Drug Designation ,Fast Track Designation ,Northx Biologics ,Markets ,